3 February 2022
23 November 2021
Theramex holds the marketing authorisation for FemSeven® 50, 75 and 100 (estradiol), FemSeven® Conti (estradiol/levonorgestrel) and FemSeven® Sequi (estradiol/levonorgestrel) in the UK and Europe since acquiring these products from Teva Pharmaceuticals Ltd on 1st February 2018.
Non-patient-safety related quality issues were brought to our attention resulting in the gradual withdrawal of the FemSeven® portfolio from the market. We have since worked diligently to fix these issues and we are in the process of completing all of the necessary quality testing to bring the entire portfolio back to market.
FemSeven® Conti returned to the UK market in January, followed by FemSeven® 50 and 75 in September. All three products continue to be fully in stock with no supply issues anticipated.
The next product to return to market will be FemSeven® 100, which is undergoing the final testing process. It is now anticipated to return to market in Q1 2022. This will be followed by FemSeven® Sequi, with an updated timeline of Q2 2022.
We appreciate the patience and understanding of patients and healthcare professionals as we bring the portfolio safely back to market.
|Product Name||Dates of Availability|
|1. FemSeven® Conti (estradiol/ levonorgestrel)|
2. FemSeven® Sequi (estradiol/ levonorgestrel)
3. FemSeven® 50 (estradiol)
4. FemSeven® 75 (estradiol)
5. FemSeven® 100 (estradiol)
|1. Fully available|
2. Expected Q2-22
3. Fully available
4. Fully available
5. Expected Q1-22
Patients who have any questions with regards to their treatment options should speak to their general practitioner.
For pharmacists and healthcare professionals who wish to place orders for the FemSeven® Conti, please contact Alliance Healthcare via your usual channels.